Methylcap-Seq Reveals Novel DNA Methylation Markers for the Diagnosis and Recurrence Prediction of Bladder Cancer in a Chinese Population by Zhao, Yangxing et al.
Methylcap-Seq Reveals Novel DNA Methylation Markers
for the Diagnosis and Recurrence Prediction of Bladder
Cancer in a Chinese Population
Yangxing Zhao
1., Shicheng Guo
2., Jinfeng Sun
1., Zhaohui Huang
3., Tongyu Zhu
4, Hongyu Zhang
1,
Jun Gu
1, Yinghua He
1, Wei Wang
1, Kelong Ma
1, Jina Wang
4, Jian Yu
1*
1State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,
2Ministry of Education’s Key Laboratory of Contemporary Anthropology and State Key Laboratory of Genetic Engineering, School of Life Sciences and Institutes of
Biomedical Sciences, Fudan University, Shanghai, China, 3Oncology Institute of Wuxi, The Fourth Affiliated Hospital of Suzhou University, Wuxi, China, 4Department of
Urology, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China
Abstract
Purpose: There is a need to supplement or supplant the conventional diagnostic tools, namely, cystoscopy and B-type
ultrasound, for bladder cancer (BC). We aimed to identify novel DNA methylation markers for BC through genome-wide
profiling of BC cell lines and subsequent methylation-specific PCR (MSP) screening of clinical urine samples.
Experimental Design: The methyl-DNA binding domain (MBD) capture technique, methylCap/seq, was performed to screen
for specific hypermethylated CpG islands in two BC cell lines (5637 and T24). The top one hundred hypermethylated targets
were sequentially screened by MSP in urine samples to gradually narrow the target number and optimize the composition
of the diagnostic panel. The diagnostic performance of the obtained panel was evaluated in different clinical scenarios.
Results: A total of 1,627 hypermethylated promoter targets in the BC cell lines was identified by Illumina sequencing. The
top 104 hypermethylated targets were reduced to eight genes (VAX1, KCNV1, ECEL1, TMEM26, TAL1, PROX1, SLC6A20, and
LMX1A) after the urine DNA screening in a small sample size of 8 normal control and 18 BC subjects. Validation in an
independent sample of 212 BC patients enabled the optimization of five methylation targets, including VAX1, KCNV1, TAL1,
PPOX1, and CFTR, which was obtained in our previous study, for BC diagnosis with a sensitivity and specificity of 88.68% and
87.25%, respectively. In addition, the methylation of VAX1 and LMX1A was found to be associated with BC recurrence.
Conclusions: We identified a promising diagnostic marker panel for early non-invasive detection and subsequent BC
surveillance.
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Introduction
Bladder cancer (BC) is one ofthe leading causes of cancer-related
morbidity and mortality and the sixth most common cancer in the
world [1]. In China, the incidence of BC continues to rise [2]. BC
incidenceincreaseswithage;theaverageageatthetimeofdiagnosis
is approximately 60 years, and it is 3 times more common in men
thaninwomen[3].Smokingandexposuretocarcinogenshavebeen
identified as risk factors [4]. Approximately 75–80% of new BC
cases occur as superficial or carcinoma in situ lesions, whereas the
remaining20–25%presentasamoreadvanceddisease,withapoor
prognosis. However, even in the superficial tumors, only 20% are
curable. Approximately 60–70% of patients will relapse within 5
years, and 10–20% of tumors will progress to a more aggressive
disease [5], which necessitates frequent monitoring for disease
recurrence [6]. Cystoscopy is the most common diagnostic BC
procedure, and it shows high sensitivity (SN) and specificity (SP).
However, cystoscopy requires high operator proficiency, and the
invasive nature of cystoscopy reduces its value as a screening tool.
Other optimal methods are needed for the early, non-invasive
detection and surveillance of BC.
The epigenetic facet of the genome connects the genotype of an
individualtoenvironmentalinfluencesthatshapetheheritablegene
transcription pattern and therefore influence the phenotype of the
cell [7]. Regulation at the epigenetic level is critical for the
development of higher eukaryotes [8], and aberrant regulation
can directly and/or indirectly influence the genetic integrity and
gene expression pattern of cells, resulting in the development of
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hypermethylation of tumor-suppressor genes [10] and the global
hypomethylationofgenomicDNA[11,12,13]oftenoccurinhuman
cancers [14,15]. Recent advances have shown that the abnormal
hypermethylation of tumor-suppressor genes is an emerging
biomarker for cancer diagnosis and prognosis. In BC, several
methylated genes have been identified, and their role as urinary
markers has also been evaluated [16]. These studies have clearly
demonstrated the advantages of using multiple gene hypermethyla-
tion analyses in tissue and urine samples to obtain diagnostic and
prognostic information. For example, in our previous study, we
identifiedapanelof11methylatedgenesthatcouldbeusedasurine-
basedmarkersforBCscreening;however,thispanelhadlimitations.
The gene number in the panel was too large for convenient clinical
testing, and the specificity was insufficient [17]. To improve the
efficiency of diagnosis and identify gene targets that can predict
recurrence or progression, it is necessary to find novel targets and
validate their clinical value in a large cohort. However, thus far, few
BC studies haveused a genomic-scalehigh-throughput approach to
screen for differentially methylated genes [18,19]
MethylCap-seq is a recently developed technique for the
genome-wide profiling of DNA methylation; this technique
consists of capturing the methylated DNA fragments by their
methyl-CpG binding domains (MBDs) and the subsequent deep
sequencing of eluted DNA. A salt-gradient elution classifies the
genome into fractions with different methylation states. The
profiles obtained in this way provide a detailed genome-wide map
of methylated regions and allow the detection of DNA methylation
in different genomic regions [20].
In this study, we first employed MBD MethylCap-seq to obtain
an overall methylation profile of BC cell lines (BCCs), which we
believed would provide information regarding BC-specific aber-
Table 1. Summary of the clinical-pathological data of urine samples from bladder cancer patients and controls.
Bladder cancer Normal control
Nontumor urinary
lesions Surgery resect Clinical cystoscope
n=212 n=149 n=41 n=21 n=48
Gender
F 4 67 11 63 1 4
M 166 78 25 17 34
Age
– 3 0 18100
31–40 1 14 4 1 2
41–50 27 29 8 4 1
51–60 41 23 6 2 4
61–70 44 26 9 4 6
71– 98 49 13 10 35
Range 29–91 22–90 16–89 35–88 31–90
Median 69 61 61 69 72
Mean6SD 66.85612.74 59.77617.14 60.24617.02 65.33614.44 68.85613.44
Grade
I7 5
II 120
III 25
Stage
Oa 3
I 134
II 63
III 7
IV 5
Relapse
Primary 157
Recurrency 55
Cystitis 17
urinary tract infection 13
kidney stones 5
prostatitis 3
Nephritis & nephrotic
syndrome
3
notes: Table 1 does not contain the information of the samples used for small cohort screening.
doi:10.1371/journal.pone.0035175.t001
DNA Methylation Markers in Bladder Cancer
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35175rant methylation. Subsequently, the DNA from the urine of BC
patients was screened for the top 100 hypermethylated targets
from BCCs to identify BC-specific methylation sites. This number
gradually decreased, and the marker quality improved during the
screening process steps. Finally, we acquired a novel set of
diagnostic DNA methylation markers that may be used for the
early, non-invasive detection and surveillance of BC.
Materials and Methods
Patient and control sample collection
With informed consent and the approval of Medical Institutional
Review Board of Zhongshan Hospital, Fudan University, urine
specimens were collected from 212 patients with a confirmed BC
diagnosis, 41 patients with noncancerous urinary lesions hospital-
izedduringthesametimeperiod,and149normalcontrols.Agroup
of paired voided urine samples was also collected from the 21 BC
patients before and after surgery that included transurethral
resection of bladder cancer plus intravesical chemotherapy
(TURBC+IC). In addition, another group of 48 urine samples was
collected from patients strongly suspected of having a malignant
bladder tumor. All the BC patients and controls came from two
hospitals: the Urology Department at Zhongshan Hospital,
Shanghai, China and the No. 2 Shimen Street Community Health
Center, Jingan District, Shanghai. The samples were collected
between 2006 and 2009. The tumor-node-metastasis (TNM)
staging/classification of the BC patient samples was determined
according to American Joint Committee on Cancer guidelines [21]
(Table 1). The samples (50 mL of fresh urine) were centrifuged at
3,000 rpmfor10 minutes.Thesupernatantwasthendecanted,and
the pellet was washed once with 16phosphate buffer saline (PBS)
and immediately frozen at 280uC.
Figure 1. General characteristics of BCC-specific DNA methylation patterns determined by MBD methylCap-seq. The genomic context
is defined as those found in the UCSC database. The featured differential methylation region (DMR) distribution in BCCs and BMs: (A) general
distribution; (B) distribution in refGene; (C) distribution in both refGene and CGI.
doi:10.1371/journal.pone.0035175.g001
DNA Methylation Markers in Bladder Cancer
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35175DNA Methylation Markers in Bladder Cancer
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35175Cell lines and normal bladder mucosal tissue
Two BCCs, T24 (ATCC No: HTB-4) and 5637 (ATCC No:
HTB-9), were purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and cultured until they reached
the log phase in L-DMEM medium containing 10% fetal bovine
serum (FBS) at 37uC in a 5% CO2 humidified incubator. The cells
were harvested by scraping, and the cell pellets were rinsed twice
with 16 PBS. Two normal bladder mucosal tissues (BM1 and
BM2) were obtained from healthy organ donors. For economic
reasons, the two BCCs were pooled to construct the BCC library,
as were the two BM samples. In this way, we could acquire all of
the methylation information from each of the 2 samples.
MBD-methylCap-sequencing
A DNA preparation from frozen tissues and cell lines was
generated using a conventional proteinase K/organic extraction
method as previously described [22]. Equal amounts of DNA from
the 5637 and T24 cells were combined to form the BCC library,
and equal amounts of DNA from the BM1 and BM2 cells were
combined to form the BM library. In 1.5-mL centrifuge tubes,
1.5 mg of the combined DNA samples (BCC or BM) in 100 mlT E
buffer were sonicated to yield the desired size range (200–300 bp).
End-repair, adenosine base addition and adaptor ligation steps
were performed as previously described [23].
The commercial MethylMiner
TM Methylated DNA Enrich-
ment Kit (Invitrogen Inc., Carlsbad, CA, USA) was used to select
methylated DNA for sequencing. For each group, 1.2 mg of the
treated DNA was processed according to the manufacturer’s
protocol. After a NaCl gradient elution, we collected the final two
fractions of highly methylated DNA, which corresponded to 1 M
and 2 M NaCl concentrations. The spike-in DNA control supplied
by the kit was used to confirm the accuracy of the assay. The
recovered DNA (in the nanogram range) was quantified by
Qubit
TM (Invitrogen), and 12 cycles of PCR amplification were
performed to obtain enough material (in the microgram range) for
deep sequencing. Finally, 1 mg of the PCR product was applied to
the Genome Analyzer II (Illumina, Inc., San Diego, CA) to
generate 75 bp-long unpaired reads. PCR duplicates were
removed from the analysis. We used BWA alignment tools with
the default settings to map these reads to the hg19 human genome
reference assembly (UCSC) [24]. Next, the peaks (hypermethy-
lated regions) were identified using MACS software [25], and the
human CpG islands (CGIs) were downloaded from the UCSC
database. The genomic methylation profile generated was
uploaded to a public database (Gene Expression Omnibus: GSE
33839)
MSP and BSP
Bisulfite conversion and PCR analysis were performed as
previously described [22]. The bisulfite sequencing PCR (BSP) and
methylation-specific PCR (MSP) primer pairs were designed with
the assistance of appropriate online software (http://www.
urogene.org/methprimer/index1.html; Table S1, Table S2). The
MSP products were cloned and verified by sequencing. The in vitro
methylated DNA from the 5637 and T24 cells was obtained with
the CpG methyltransferase M. Sss I (NEB) and used as a positive
control. Water was used as a no-template control. Bisulfite
sequencing was performed as previously described [17], and the
PCR amplicons were gel-purified and cloned into a pBS-T II
vector (TianGen Incl., Beijing, China). At least 5 clones were
individually sequenced to ascertain the methylation patterns of the
targeted locus. The BSP methylation percentage was calculated as
the number of methylated cytosines divided by the total number of
cytosines in all of the amplicons analyzed.
Statistics
The major statistical endpoints in this study involved comparing
the methylation statuses of genes thought to be associated with BC
and their relevant clinical variables in the control and cancer
patients. The presence or absence of methylation using MSP was
evaluated to determine the associations between methylation status
and cancer or its clinical variables using cross-tabulations and the
appropriate x
2 or Fisher’s exact t-tests. The association of BC
recurrence with gene methylation and clinical variables was
assessed by means of uni- and multivariate logistic-regression
analyses. The outcome selected for the follow-up analysis was the
cumulative hazard of recurrence, which was defined as the time
from BC diagnosis to the date of tumor recurrence. Uni- and
multivariate Cox proportional hazards models were used to assess
the effects of gene methylation and other clinical variables of
disease recurrence. The cumulative recurrence hazard curve was
generated by the Kaplan-Meier method and verified by the log-
rank test. All the statistical calculations were performed using the
SPSS 13.0 software statistical package (SPSS Inc., Chicago, IL).
Two-sided P values less than 0.05 were considered significant.
Figure 2. Representative BSP confirmation of the MBD methylCap/seq library. The Wig picture from the UCSC database is on the left, and
the BSP result where at least 5 clones were sequenced for each locus is on the right. The black circle indicates methylated C in the CpG context; the
white circle indicates unmethylated C in the CpG context.
doi:10.1371/journal.pone.0035175.g002
Figure 3. Flow chart describing the number of samples and
candidate genes in the screening process. MBD methylCap-seq
information was used to select genes differentially hypermethylated in
bladder cancer. The sample number in the figure refers to that of the
screening process. The methylation status of the target gene was
screened in samples with different sizes. In this phase, the number of
samples progressively increased, while the number of genes pro-
gressively decreased.
doi:10.1371/journal.pone.0035175.g003
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Genomic methylation profiling of the BCC and BM
libraries revealed characteristic methylation patterns in
BC
We profiled the genome-wide DNA methylation status of the
BCC and BM libraries by generating MBD-methylCap-enriched
DNA libraries. The MBD-enriched fractions were subjected to
high-throughput sequencing using an Illumina Genome Analyzer
II to obtain comprehensive methylation maps. Conceptually, the
hypermethylated DNA fragments were enriched during the library
construction process; therefore, the acquired sequencing reads
correspond with the hypermethylated regions on the genome.
Deep sequencing of the prepared BCC and BM libraries produced
approximately 6 million reads (75 bases/read) for each library,
which were derived from approximately 470 million bases
(Table S3). This amount of sequencing bases could cover the
genomic CGI in approximately 10 times the depth. Thus, the data
sets successfully provided genome-wide information.
When these reads were mapped into the genome, the uneven
distribution formed peaks that represent the hypermethylated
regions of the genome. In total, we obtained 210,051 peaks (mean
length of peaks: 778 bp) in the BCCs and 229,538 peaks (mean
length of peaks: 659 bp) in the BMs (P,0.001, MACS2.0;
Table S3).
To obtain the relative methylation information, we compared
the peaks between the BCCs and the BMs. Nearly two-thirds of
the total peaks were common between the two libraries, and we
ignored them for this analysis. The remaining one-third of the
peaks were unique to either the BCCs or the BMs, which we
termed the differentially-methylated regions (DMRs) that repre-
sent the relatively high methylation status of the genomic regions
compared with its counterpart. We obtained 70,432 and 83,690
DMRs in the BCCs and the BMs, respectively (Table S3, Figure 1
A). This large amount of DMR was scattered within different
genomic contexts, and we analyzed the association of the DMR
with the different genomic contexts. The refGene-related DMR
was 55,237 and 45,522 in the BCCs and the BMs, respectively,
indicating a roughly balanced distribution in both libraries (Table
S3, Figure 1 B). However, when DMRs within the CGIs were
investigated, we found that the BCCs retained 21,179 DMRs,
while the BMs retained only 1,945; this represents a ten-fold
difference. When the DMRs that occurred within the CGIs of the
refGene were studied, the BCCs and the BMs contained 4,256 and
201 DMRs for each library, respectively. Lastly, when promoter
involvement was calculated, 1,627 and 66 DMRs were associated
in this region in the BCCs and the BMs, respectively (Table S3,
Figure 1 C). Taken together, aberrant hypermethylation occurred
more frequently in the CGIs and the promoter regions of the
BCCs. The following studies of the methylation marker selection
focused on BCC promoters.
Validation of the distinct BCC methylation profile using
bisulfite sequencing
To confirm that the library accurately reflected the real
methylation status of the studied material, we selected 24 different
hypermethylated targets for bisulfite sequencing verification. Of
these, 22 targets were scattered within the 1,627 promoter-related
DMRs in the BCCs, including 17 from the top 100 targets and 5
from the 100 to 1,627 range; the other 2 targets were from the 66
DMRs in the BMs. Encouragingly, among the 24 targets being
verified, the BSP results of 23 genes were highly consistent with the
methylation information acquired in the library (a representative
result is shown in Figure 2, Table S4), suggesting that the BCC
and BM libraries were highly reliable for methylation information.
To assess the potential of the library for suggesting clinical
diagnostic targets, we searched the methylation information of
targets identified in our previous work in these two libraries [17]. A
total of 90% (19/21) of those targets were hypermethylated in the
BCC library (data not shown). In addition, we also investigated the
BC-specific markers reported by others [19,26]. Eight of the 9
targets were located in our BCC library as hypermethylation loci.
Taken together, the present BCC and BM libraries provided
sound hypermethylation information with respect to BC status.
Table 2. The diagnosis performance of the 9 studied methylation targets, individually or in panel, in bladder cancer versus normal
or nontumor urinary lesion controls.
Bladder cancer Bladder cancer vs Normal control (n=149) Bladder cancer vs Nontumor urinary lesions (n=41)
Sensitivity(%) Specificity (%)
AUC(95%
CI) PPV NPV P
Specificity
(%)
AUC(95%
CI) PPV NPV P
(pos./total) (neg./total) (%) (%) (neg./total) (%) (%)
VAX1 42.45(90/212) 95.31(142/149) 73.3(68.0–78.6) 92.78 53.79 ,0.0001 87.81(36/41) 59.5(52.5–66.5) 94.74 21.43 0.0002
KCNV1 36.92(84/212) 93.96(140/149) 71.3(65.7–76.8) 90.32 52.24 ,0.0001 95.12(39/41) 60.5(53.6–67.5) 97.67 23.35 ,0.0001
ECEL1 26.89(57/212) 97.31(145/149) 70.8(64.7–76.8) 96.55 48.33 ,0.0001 97.56(40/41) 59.3(51.7–67.0) 98.28 20.51 0.0002
TMEM26 26.42 (56/212) 96.64(144/149) 69.4(62.9–75.8) 91.80 48.00 ,0.0001 97.56(40/41) 60.3(52.5–68.0) 98.25 20.41 ,0.0001
PROX1 24.53(52/212) 98.66(147/149) 71.1(65.0–77.3) 96.30 47.88 ,0.0001 100.0(41/41) 59.1(61.2–66.9) 100.0 20.40 ,0.0001
TAL1 24.83(52/212) 98.66(147/149) 72.5(66.8–78.3) 93.44 48.51 ,0.0001 100.0(41/41) 60.4(52.9–68.0) 100.0 20.40 ,0.0001
SLC6A20 15.57(33/212) 97.89(146/149) 69.7(62.3–77.0) 91.67 44.92 ,0.0001 100.0(41/41) 59.3(50.2–68.4) 100.0 18.64 0.0039
LMX1 9.43(20/212) 98.66(147/149) 67.1(57.5–76.8) 90.91 43.36 ,0.0001 100.0(41/41) 58.8(47.5–70.1) 100.0 17.60 0.0404
Panel 1 76.89(163/212) 88.59(132/149) 82.8(78.5–87.1) 90.56 72.93 ,0.0001 85.36(35/41) 84.3(79.1–89.5) 96.45 41.67 ,0.0001
CFTR 52.35(111/212) 96.64(144/149) 77.4(72.6–82.1) 95.69 58.78 ,0.0001 97.56(40/41) 63.8(57.1–7.02) 99.11 28.37 ,0.0001
Panel 2 88.68(188/212) 87.25(130/149) 89.9(86.7–93.2) 90.82 84.42 ,0.0001 85.36(35/41) 90.0(85.9–94.2) 96.91 59.32 ,0.0001
Panel 1: VAX1,KCNV1,TAL1,PPOX1.
Panel 2: CFTR,VAX1,KCNV1,TAL1,PPOX1.
doi:10.1371/journal.pone.0035175.t002
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potential biomarkers generated 8 gene targets
Presented with the large aberrant methylation information
provided by methyCap-seq, we needed a method to filter the BCC
methylation results to identify feasible BC markers. We adopted
the strategy of beginning the screening process with a large
number of targets in a few samples and gradually reducing the
targets with an increase in samples (Figure 3). When subjected to
the MSP limitations, only the top 104 of the 1,627 hypermethy-
lated promoters of the BCCs were screened in the urine DNA
samples of 8 normal controls (BNs); the same BCC and BM
samples used in the MethylCap-seq portion of the study were
included as controls. In these conditions, only the targets that
showed methylation in at least one of the two BCCs but not in
more than 2 of the 8 BN proceeded to the next screening (a
representative MSP result is shown in Figure S1). Because they did
not meet these criteria, 55 targets were removed from the first
round of screening. Forty-nine targets proceeded to the second
round of urine DNA screening from an additional 8 BNs and 18
BC patients. We selected the targets that showed methylation in at
least 3 of the 18 BC samples but 0 or 1 of the 8 BN samples. In this
stage, 8 genes (VAX1, KCNV1, ECEL1, TMEM26, TAL1,
PROX1, SLC6A20, and LMX) met the conditions and were
selected for their potential to discriminate BC from BN (Figure 3).
Assessment of the diagnostic value of the 8 targets in
a large cohort
To ensure that the potential of the BC candidate targets was
reliably evaluated, we screened the 8 candidates in an independent
testcohortwithalargesamplesize.Weobtainedurinesamplesfrom
a large cohort (n=402) that included 212 BC patients, 149 normal
controls, and 41 patients with noncancerous urinary lesions.
The methylation frequency of the 8 novel genes in the urine
DNA from BC patients (212 cases) ranged from 9.43% to 42.45%,
whereas the methylation frequency in normal controls (149 cases)
ranged from 1.34% to 6.04%. All 8 targets showed a significant
difference between the tumors and normal controls (P,0.0001),
which favorably argued for their potential use as diagnostic
markers (Table 2).
To differentiate tumor-specific methylation from possible
methylation associated with benign disease, 41 noncancerous
urinary lesions were included in our study (Tables 1 and 2). The
methylation frequency of the 8 genes in this patient group ranged
from 0.00% to 12.19%, supporting the notion that the origin of
the hypermethylation was more closely linked to tumors than
benign disease (P,0.04; Table 2). Therefore, these 8 targets may
potentially serve as markers for the clinical detection of BC and to
distinguish BC from normal controls and benign urinary lesions.
Given the heterogeneous nature of tumor methylation, a single
methylated marker cannot provide adequate SN and SP for tumor
diagnosis [27]. Therefore, combining a group of genes as a panel
was an alternative option [28]. Taking the area under the curve
(AUC) as a judgment of diagnostic ability, a combination of 4
genes (VAX1, KCNV1, TAL1, PROX1) was selected to form
a diagnostic panel, which showed an SN of 76.89% and SP of
88.59% (Table S5).
To further improve the diagnostic potential of this panel, we
added CFTR and SALL3, the two top BC targets from our
previous work [17], which were also located within the 1,627
promoters related to DMRs in the BCCs. The CFTR exhibited
decent potential for diagnosing BC, with an SN and SP of 52.36%
and 96.64%, respectively (Table 2). However, SALL3 did not
present a good SP in a large-cohort evaluation and was therefore
removed (data not shown). Finally, a 5-gene panel (VAX1,
KCNV1, TAL1, PROX1 and CFTR) was adopted that revealed
diagnostic efficiency, with SN, SP, positive predictive value (PPV),
and negative predictive value (NPV) of 88.68%, 87.25%, 90.82%,
and 84.42%, respectively (Table 2). The similar results was also
Figure 4. The relationship between gene methylation (hazard
ratio) and BC tumor characteristics. A multiple univariate logistic
regression was performed with the use of methylation data of the 9
genes to evaluate the relationship between gene methylation and the
clinicopathological characteristics of BC. The details are described in the
text. *P,0.05.
doi:10.1371/journal.pone.0035175.g004
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of 24 BC and 22 controls (data not shown).
The diagnostic ability of the five-gene panel is
comparable to cystoscopy
The performance of the five targets in the evaluation of
suspected clinical patients is critical. Therefore, we used MSP to
assess the urine of patients who had suspected uroepithelial
malignancies. Of the 48 patients, 32 BC patients were eventually
confirmed by cystoscopy, and 25 of these were MSP-positive for at
least one of the five genes. Of the 16 patients who did not show
malignancy by cystoscopy, 14 were negative for MSP. Therefore,
the 5-gene target showed good conformity with cystoscopy
(81.25%; 25 positive and 14 negative in a total of 48 patients by
both procedures).
The five-gene panel could also predict the effectiveness
of surgical resection
All 21 (100.0%) of the BC patients were MSP-positive for at
least 1 of the 5 genes before surgery, whereas only 2 of the 21
(9.5%) BC patients retained MSP-positive genetic loci after surgery
(P,0.0001). These results add additional support to our previous
discovery and hypothesis [17] and corroborate the idea that a close
relationship exists between the methylation observed in urine
sediment and the corresponding bladder tumor.
The hypermethylation of VAX1 and LMX1A is important
for predicting cancer recurrence
In addition to the relationship between the gene methylation
status and the malignant phenotype of the tumor itself, we also
studied the association between methylated targets and different
clinical parameters.
The multiple univariate logistic-regression analysis of 9 gene
targets (VAX1, KCNV1, ECEL1, TMEM26, TAL1, PROX1,
SLC6A20, LMX1A and CFTR) showed that VAX1 and LMX1A
methylation was more common in urine samples from recurrent
cases than in samples from primary cases in the initial analysis of
212 BC patients (primary: 157; recurrence: 55), with HR=2.37
(CI 95%, 1.27 to 4.44, P,0.05) and HR=2.59 (CI 95%, 1.01 to
6.65, P,0.05), respectively (Figure 4). Multivariate logistic-
regression models revealed that the HR of VAX1 and LMX1A
were 2.27 (95%CI, 1.20 to 4.32; P=0.047) and 2.63 (95% CI,
1.01 to 6.85; P=0.012), respectively (Table 3). And the association
was more evident when these two genes were analyzed in
combination, with HR of 4.73(95%CI, 1.39 to 16.08; P=0.013).
The close association of these two genes with recurrence was
evident in the follow-up data based on 145 cases (no recurrence:
108; recurrence: 37) with intact follow-up information. Multivar-
iate Cox proportional hazard models revealed that the HR of
VAX1 and LMX1A were 2.11 (95%CI, 1.08 to 4.11; P=0.029)
and 3.31 (95% CI, 1.27 to 8.59; P=0.014; Table 4), respectively.
The combination of the two genes revealed a more high HR of
Table 3. The multivariate hazard ratios and 95% confidence intervals for the estimated risk of recurrence among recurrent cases
compared with primary cases according to LMX1A and VAX1 methylation (separated or combined) and clinical variables.
Clinical variables
Number of
case
Number of
recurrence (%) HR 95% CI P
Overall 212 55 25.94%
LMX1A Methylation Negative 192 46 23.96%
Positive 20 9 45.00% 2.63 (1.01,6.85) 0.012
Gender Female 46 15 32.61%
Male 166 40 24.10% 0.69 (0.33,1.42) 0.555
Muscle invasion Absent 178 44 32.35%
Present 34 11 24.72% 1.76 (0.71,4.37) 0.217
Stage 0a+I 137 36 26.28%
II+III 75 19 25.33% 1.00 (0.46,2.16) 0.920
Grade I 73 23 31.51%
II+III 139 32 23.02% 0.59 (0.29,1.18) 0.171
VAX1 Methylation Negative 122 23 18.85%
Positive 90 32 35.56% 2.27 (1.20,4.32) 0.047
Gender Female 46 15 32.61%
Male 166 40 24.10% 0.80 (0.38,1.68) 0.313
Muscle invasion Present 178 44 24.72%
Absent 34 11 32.35% 1.79 (0.71,4.49) 0.226
Stage 0a+I 137 36 26.28%
II+III 75 19 25.33% 0.96 (0.45,2.08) 0.998
Grade I 73 23 31.51%
II+III 139 32 23.02% 0.61 (0.30,1.24) 0.134
LMX1A &VAX1 Negative 200 48 24.00%
Positive 12 7 58.33% 4.73 (1.39,16.08) 0.013
Hazard Ratio are reported on the basis of the multivariate logistic-regression model.
doi:10.1371/journal.pone.0035175.t003
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Meier plots revealed that the cumulative hazard of recurrence in
methylated and unmethylated VAX1 and LMX1A differed
significantly (P=0.034 and P=0.013, respectively). More sigfi-
cance was obtained when VAX1 and LMX1A analyzed together
(P,0.0001, Figure 5). The validation in a small independent
cohort consisted of 24 BC and 22 controls revealed the same
tendency with HR 9.11(95%CI, 0.89 to 93.7, P=0.063) for the
two gene combination with marginal significance owning to the
small sample size perhaps (data not shown). These observations
underscore the importance for determining the methylation status
of VAX1 and LMX1A for the prognosis of disease recurrence.
In additioin to LMX1/VAX1, We also tried to assess the
involvement of the other 7 genes in format of two-gene pair
combination. The hypermethylation status in some of these genes
showed high coincidence with BC recurrence, however this
association can not be sustained in the analysis of the follow-up
data. Therefore the aberrant methylation in these genes might be
the results rather than the trigger of BC recurrence.
The methylation status of ECEL1 and TMEM26 was
significantly related to a high degree of tumor differentiation,
with HR=2.43 (95% CI, 1.19 to 4.97; P=0.01) and 2.32 (95%
CI, 1.11 to 4.85; P=0.03), respectively (Figure 4), suggesting that
they are involved in BC malignancy and progression.
Discussion
In this study, we reported the details of establishing biomarkers
related to BC methylation, which are as follows: (i) the global
methylation profile of both BCCs and BMs by MBD methylCap-
seq; (ii) aberrant DNA BC methylation maps through the
comparison of the methylation profile of BCCs with BMs; (iii)
a panel of promising methylation targets specific to BC; (iv) two
informative gene targets informative for BC recurrence; and (v)
two methylation genes associated with BC histological differenti-
ation.
Established cancer cell lines are generally expected to share
many (if not all) genetic and epigenetic features with tumors in vivo,
and cancer cell lines are widely used for tumorigenesis studies. A
study of human colorectal cancer found that 6 cancer cell lines had
methylation patterns that were very similar to the primary tumor
with respect to 60 methylation gene targets [29]. Therefore, we
Table 4. The univariate and multivariate analyses of the recurrence prognostic values of various factors according to VAX1 and
LMX1A methylation (separated or combined) and clinical variables.
Clinical
variables
Number of
case
Number of
recurrence (%) Cox-ranked univariate Cox-ranked multivariate
HR 95% CI P HR 95% CI P
Overall 145 37 25.5%
VAX1 Negative 93 18 19.4%
Positive 52 19 36.5% 1.92 1.00,3.65 0.048 2.11 (1.08,4.11) 0.029
Gender Female 29 7 24.1%
Male 116 30 25.9% 0.86 0.38,1.95 0.711 0.72 (0.31,1.67) 0.440
Muscle invasion Absent 128 33 25.8%
Present 17 4 23.5% 1.05 0.37,2.96 0.928 0.93 (0.30,2.85) 0.893
Treatment TURBT+IC 78 16 20.5%
PC 67 21 31.3% 0.93 0.48,1.79 0.822 0.84 (0.42,1.67) 0.614
Stage 0a+I 97 26 26.8%
II+III 48 11 22.9% 1.14 0.56,2.30 0.721 1.30 (0.61,2.77) 0.500
Grade I 46 10 21.7%
II+III 99 27 27.3% 0.77 0.37,1.60 0.488 0.66 (0.30,1.43) 0.290
LMX1a Negative 136 32 23.5%
Positive 9 5 55.6% 3.08 1.20,7.95 0.019 3.31 (1.27,8.59) 0.014
Gender Female 29 7 24.1%
Male 116 30 25.9% 0.86 0.38,1.95 0.711 0.83 (0.36,1.89) 0.649
Muscle invasion Absent 128 33 25.8%
Present 17 4 23.5% 1.05 0.37,2.96 0.928 1.09 (0.35,3.36) 0.881
Treatment TURBT+IC 78 16 20.5%
PC 67 21 31.3% 0.93 0.48,1.79 0.822 0.88 (0.45,1.75) 0.724
Stage 0a+I 97 26 26.8%
II+III 48 11 22.9% 1.14 0.56,2.30 0.721 1.28 (0.59,2.75) 0.529
Grade I 46 10 21.7%
II+III 99 27 27.3% 0.77 0.37,1.60 0.488 0.67 (0.31,1.46) 0.312
LMX1a & VAX1Negative 140 33 23.6%
Positive 5 4 80.0% 6.40 2.24,18.29 0.001 7.25 (2.41,21.79) 0.014
Hazard ratios, 95% confidence intervals, and their conrresponding P-values were calculated using univariate and multivariate Cox proportional hazard medels.
doi:10.1371/journal.pone.0035175.t004
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used the clinical sample screening to gather BC-specific methyl-
ation information.
Many genes have been reported to be hypermethylated in BC.
Recently, studies with new screening approaches, such as
methylation arrays, have identified methylation markers with high
SN and SP [30,31,32]. This genomic screening approach provides
an efficient and reliable method for establishing an aberrant
methylation profile associated with disease. We adopted the MBD
methylCap-seq technique in our studies because it is an open
platform for novel methylation loci without prior local sequence
knowledge. Therefore, we screened BCCs and compared them to
BMs to attempt to discover aberrant BC methylation information.
In addition to the gene promoter methylation status, we
obtained the overall genome-wide methylation profile information,
which includes different genomic contexts, such as enhancers,
downstream regulators, the 59UTR, exons, introns and micro-
RNAs. The validity of the comparative methylation statuses was
confirmed by BSP and MSP. This represents more DNA
methylation information for different genomic context features
than array methodology, which is limited by probe sequences.
A diagnostic method with high SN and SP is important for any
clinically related test. There have been several reports concerning
the methylation profiling of urine sediments for BC detection
[17,19,26,33,34,35,36]. The techniques used in these studies
include conventional MSP, qPCR, nested-MSP, and MethyLight.
The diagnostic marker panels are usually composed of 3 to 11
gene targets that range in SN from 77% to 94% and SP from 67%
to 100% (Table S6). In contrast, we obtained moderate SN and SP
rates of 88.68% and 87.25%, respectively, but these values may be
valuable to the Chinese population because there may be disparity
between different ethnic populations regarding BC-specific
methylation markers [17]. We noted that, except for the wide
variation of the diagnostic performance from the different authors,
the gene targets were also different. The possible explanations
include the different methods and populations used in each of
these studies.
To obtain reliable SN and SP values, sufficient numbers for
statistic power are necessary. In many of these early studies, small
control groups ranging from 6 cases to 20 cases were used
[17,31,33,34,35,36], which would affect the reliability of the
biomarker investigated, particularly the diagnostic SP. Recently,
Reiner et al. analyzed 59 control cases [19], and Chung analyzed
110 control cases to correct the problems of small control sample
sizes [26] (Table S6). However, in our study, 149 normal controls
were analyzed in addition to 212 BC patients. This is perhaps the
largest case-control study conducted to analyze urine methylation
markers to date. Furthermore, we selected 41 patients with
noncancerous urinary lesions to differentiate malignant tumors
from benign lesions. To evaluate the possible origin of these
targets, their methylation status was investigated in the urine
samples from patients before and after the surgical removal of BC.
When comparing the diagnostic performance of these methylated
targets with cystoscopy, a decent consistency was obtained (an
accuracy of 81.25%). All of these procedures were conducted in
our study to develop a reliable BC diagnostic panel more objective
and less invasive than cystoscopy.
Cancer recurrence presents complex and formidable problems.
The detection of BC recurrence primarily depends upon invasive
cystoscopy with low compliance, resulting in the need to find
a better marker. A new technique for the early prediction of BC
recurrence should be able to instantly distinguish the disease risk
and provide the proper therapy and necessary intensive vigilance
for patients with a high risk of recurrence. This would improve the
treatment efficiency and increase the survival interval for high-risk
patients while simultaneously reducing unnecessary treatment
procedures or vigilance measures, thereby lessening the economic
burden on patients at low risk. However, little was previously
known regarding the association between DNA methylation and
BC recurrence. Tada et al. have found [37] that overexpression of
the MDR1 gene may be a prognostic marker for intravesical BC
recurrence; however, methylation of its promoter negatively
regulates MDR1 expression. Nagraes et al. [38] sought to
investigate whether the aberrant DNA methylation of cancer-
associated genes was related to urinary BC recurrence and
suggested that RARB and RASSF1A gene methylation should be
considered potential diagnostic markers, particularly in studies
aiming at early recurrence detection. In this study, we found that
VAX1 and LMX1A methylation was highly associated with tumor
recurrence, suggesting that methylated VAX1 and LMX1A may
serve as useful biomarkers to predict BC recurrence.
Currently, the rationality for DNA hypermethylation being
a tumor biomarker involves their biological functional relevance in
the tumor entity, typically in which DNA hypermethylation in the
Figure 5. The role of urine DNA VAX1 methylation markers in the clinical prognosis of bladder cancer. Kaplan-Meier estimations of
recurrence-free survival in the follow-up cohort of 145 patients according to the presence of methylated VAX1 and LMX1A (A and B). VAX1 or LMX1A
methylation was significantly associated with poor prognosis for BC patients (P=0.034 and P=0.013, respectively). Analysis of two genes combined
shows more statical power (P,0.0001).
doi:10.1371/journal.pone.0035175.g005
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cases) often results in transcription silencing of that gene. Our
present study represents the first confirmation for the hypermethy-
lation of 8 genes in bladder cancer, although 4 of them were found
to be linked with other tumors before. PROX1 and LMX1 are
both hypermethylated with expression silence in breast cancer and
gastric cancer [39,40], representing 2 in line with the presumed
epigenetical markers in the present panel; whereas the expression
of TAL1 was closely associated with T cell acute lymphoblastic
leukemia and hypermethylation of SLC6A20 with malignant
mesothelioma, but the exact underlying mechnism is to be
elucidated yet [41,42]. The remaining other 4 genes, VAX1
KCNV1, ECEL1 and TMEM26, were found in the present study
to be hypermethylated in BC, but there were no any background
record that provided mechanisms in the carcinogenesis and
development of any cancer, let alone BC. VAX1 encodes
a homeodomain transcription factor known for its role in eye
and optic chiasm development [43]; KCNV1 is a gene responsible
for a protein related to voltage-gated K(+) channel (Kv) family
[44]; ECEL1 encodes a member of the M13 family of
endopeptidase [45], while TMEM26 transcripts a protein to be
regulated by hedgehog signalling im the mouse limb [46]. Given
their hypermethylation status in BC, probabaly these genes also
follow the general rules of TSG inactivation in tumor. But the
hypothesis needs further studies to prove. At this point, we are
making use of the strong association of hypermethylation with BC
and focus on the clinical significe it can make.
In using a MBD methylCap-seq procedure, we discovered
a series of genes that are frequently methylated in BC. By
sequentially screening a series of clinical urine DNA samples, an
informative BC biomarker panel was established. This panel is
capable of differentiating BC from noncancerous urinary lesions
and predicting disease recurrence, which is very important in
clinical BC management.
Supporting Information
Figure S1 The MSP profile and sequencing verification.
The MSP profile and sequencing verification of the targeted
regions of the 8 informative genes in eath of 16 BC samples and 8
normal controls. Both the electrophoretic patterns of the
representative MSP data and the sequencing verifcation are
shown. P, the positive control with the DNA of the 5637 treated in
vitro by M. SssI; N, the negative control (H2O as template). The
genomic sequence is aligned with the sequence produced by T-
vector cloned with the representative PCR prodcut.
(TIF)
Table S1 The BSP primer list.
(XLS)
Table S2 The MSP primer list.
(XLS)
Table S3 The BCC and BM MBD methylCap-seq library
characteristics.
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Table S4 BSP validation of methylation information in
BCC and BM libraries.
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Table S5 The receiver operating characteristics of the
informative gene panel for bladder cancer detection.
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Table S6 The comparison of the performance of the
target sets in urine DNA methylation from different
authors.
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